Search

CX-2009

CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).

Colistimethate

Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms.

NRP369

NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

CYC116

In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers.

Oftasceine

It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

Aspartyl-alanyl-diketopiperazine

Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).

EU204

EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.

CG7870

CG7870 is an oncolytic virus therapy for prostate cancer.

Eldelumab

MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory

Fiboflapon